Latest filings (excl ownership)
8-K
Other Events
21 Dec 23
8-K
Other Events
18 Dec 23
25-NSE
Exchange delisting
10 Jul 23
8-K
Departure of Directors or Certain Officers
3 Jul 23
DEF 14A
Definitive proxy
2 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
24 May 23
RW
Registration withdrawal request
24 May 23
PRE 14A
Preliminary proxy
23 May 23
10-Q
2023 Q1
Quarterly report
18 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 May 23
8-K
Departure of Directors or Certain Officers
5 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
8-K
Termination of a Material Definitive Agreement
25 Apr 23
8-K
Departure of Directors or Certain Officers
18 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives
30 Mar 23
8-K
Cost Associated with Exit or Disposal Activities
1 Mar 23
8-K
NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx
27 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 22
8-K
Departure of Directors or Certain Officers
1 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
8 Nov 22
8-K
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies
25 Aug 22
8-K
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
12 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
4 Aug 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
31 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress
12 May 22
8-K
Other Events
19 Apr 22
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
8-K
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
7 Apr 22
EFFECT
Notice of effectiveness
1 Apr 22
424B5
Prospectus supplement for primary offering
31 Mar 22
Latest ownership filings
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13D/A
ADAMS STREET PARTNERS LLC
27 Jun 23
SC 13D/A
Longitude Capital Partners II, LLC
16 Mar 23
SC 13D/A
Longitude Capital Partners II, LLC
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
SC 13G/A
Kryzanowski John A
20 Jan 23
4
ASHISH KHANNA
5 Jan 23
4
NORBERT G RIEDEL
5 Jan 23
4
ANDREW KIDD
5 Jan 23
SC 13G/A
Kryzanowski John A
24 Jun 22
SC 13G/A
Kryzanowski John A
24 Jun 22
SC 13G/A
Kryzanowski John A
24 Jun 22
SC 13G
Kryzanowski John A
24 Jun 22
4
Adam Koppel
31 May 22
4
Gilmore Neil O'Neill
31 May 22
4
Joan W. Miller
31 May 22
4
Terry P Gould
31 May 22
4
Henry O Gosebruch
31 May 22
4
ROBERT J. HOMBACH
31 May 22
4
Rachel E. Sherman
31 May 22
4
PATRICK G ENRIGHT
31 May 22
4
ASHISH KHANNA
22 Feb 22
SC 13D/A
New Leaf Ventures III, L.P.
11 Feb 22
4
Joan W. Miller
18 Jan 22
4
NORBERT G RIEDEL
8 Dec 21
4
ANDREW KIDD
7 Dec 21
4
NORBERT G RIEDEL
7 Dec 21
4
ASHISH KHANNA
6 Dec 21
4/A
ROBERT J. HOMBACH
16 Nov 21
4
ROBERT J. HOMBACH
15 Nov 21
4
Gilmore Neil O'Neill
22 Oct 21
3
Gilmore Neil O'Neill
22 Oct 21
4
Joan W. Miller
1 Jun 21
4
Terry P Gould
1 Jun 21
4
Henry O Gosebruch
1 Jun 21
4
ROBERT J. HOMBACH
1 Jun 21
4
Rachel E. Sherman
1 Jun 21
4
PATRICK G ENRIGHT
1 Jun 21
4
Adam Koppel
1 Jun 21
4/A
ASHISH KHANNA
20 May 21